EN DE

evertex fabrinology limited (1470) Fair Value & Analysis

Consumer Cyclical · TW · Market cap 2.0B TWD

EF evertex fabrinology limited 1470 · TW
Price23.40 TWD
Fair Value16.05 TWD
Upside-31.4%
Quality66/100
Watch evertex fabrinology limited for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 9.5% net margin
generates free cash flow
2.83% dividend yield
Mixed vs. peers (6/13)
Moderate moat 45/100
Evidence: High Range 12.23 TWD – 19.94 TWD Share as image

Fair value as of: Jul 23, 2026

From 22 valuation models · updated 19 days ago

Share price +8.8% over the past month.

A solid business, but screening 31% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (19.94 TWD). The favourable scenario is already priced in.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

25.59 TWD 12.71 TWD Fair Value 16.05 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 12.71 TWD – 25.59 TWD · fair‑value band 12.23 TWD – 19.94 TWD · the 23.40 TWD price screens above the 16.05 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

evertex fabrinology limited (1470) currently trades at 23.40 TWD, while our model-based Fair Value estimate is 16.05 TWD, implying the stock looks roughly 31.4% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, evertex fabrinology limited generated revenue of 781M TWD at a net margin of 9.5%. Revenue declined 10.6% year over year. It earns a return on equity of 7.6%. The balance sheet holds a net cash position of 191M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 12.23 TWD (bear case) to 19.94 TWD (bull case); at 23.40 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 20% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -3% fair-value upside, at -31%, 1470 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 8.91 TWD 9.08 TWD 8.85 TWD 76
Growth DCF 10.61 TWD 12.58 TWD 15.85 TWD 72
Growth-Adj P/E 9.12 TWD 13.03 TWD 16.94 TWD 68
All 22 models by family
DCF Models
FCF DCF 10.41 TWD 12.47 TWD 16.20 TWD 38
Owner Earnings 10.04 TWD 12.00 TWD 15.55 TWD 31
5Y Revenue Exit 10.17 TWD 13.25 TWD 17.83 TWD 39
5Y EBITDA Exit 12.75 TWD 17.62 TWD 24.20 TWD 41
5Y P/E Exit 12.39 TWD 17.01 TWD 22.64 TWD 38
10Y Revenue Exit 10.04 TWD 12.57 TWD 15.42 TWD 36
10Y EBITDA Exit 11.66 TWD 15.20 TWD 19.21 TWD 37
10Y P/E Exit 11.46 TWD 14.84 TWD 18.28 TWD 35
Earnings-Based
Graham-Dodd 5.33 TWD 8.90 TWD 10.81 TWD 54
EPV 9.07 TWD 9.94 TWD 10.66 TWD 59
Multiples
P/E Multiple 12.94 TWD 17.25 TWD 21.57 TWD 63
P/S Multiple 8.43 TWD 11.25 TWD 14.06 TWD 58
P/B Multiple 10.00 TWD 13.33 TWD 16.67 TWD 55
EV/EBIT 15.86 TWD 20.24 TWD 24.63 TWD 53
EV/EBITDA 16.38 TWD 20.93 TWD 25.49 TWD 54
EV/Revenue 10.59 TWD 13.96 TWD 17.33 TWD 43
Asset-Based
NCAV (Graham) 5.91 TWD 7.92 TWD 11.82 TWD 50
Growth DCF
Growth DCF 10.61 TWD 12.58 TWD 15.85 TWD 72
Rev-Margin DCF 10.17 TWD 13.41 TWD 17.56 TWD 67
Economic Profit
Residual Income 8.91 TWD 9.08 TWD 8.85 TWD 76
ROIC Compounder 9.07 TWD 9.94 TWD 10.66 TWD 67
Growth Earnings
Growth-Adj P/E 9.12 TWD 13.03 TWD 16.94 TWD 68

Widest divergence: Multiples (13.96 TWD) versus Asset-Based (7.92 TWD). Highest evidence: Residual Income (76).

Notify me when 1470 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 781M TWD
Revenue growth (YoY) -10.6%
Net margin 9.5%
Return on equity 7.6%
Free cash flow 78.6M TWD FY2025
P/E ratio 29.4
More key figures
Operating margin 12.3%
EPS (TTM) 0.7800 TWD
Dividend yield 2.8%
EPS growth (YoY) +35.3%
Net cash 191M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 65 · Market factors (momentum, volatility) 65

Profitability 40
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 86
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 70
Distance to the 52-week high (market factor)
Net Issuance 79
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

evertex fabrinology limited engages in dyeing and finishing of textile products in Taiwan, Vietnam, Bengal, China, Cambodia, Indonesia, and internationally. The company offers Janerino, a hybrid merino wool fabric; BulkyStretch, a mono-material knit fabric; Syncellux, a cellulose synthetic blend fabric; and Tonissimo, a synthetic fleece fabric.

Full company description

evertex fabrinology limited engages in dyeing and finishing of textile products in Taiwan, Vietnam, Bengal, China, Cambodia, Indonesia, and internationally. The company offers Janerino, a hybrid merino wool fabric; BulkyStretch, a mono-material knit fabric; Syncellux, a cellulose synthetic blend fabric; and Tonissimo, a synthetic fleece fabric. It also provides functional fabrics; and fabrics for trims, pocket, and collar liners, as well as linings for casual and outdoor wears. The company was formerly known as Evertex Dyeing & Finishing. evertex fabrinology limited was founded in 1986 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

evertex fabrinology limited reported revenue of 804M TWD in FY2025 versus 895M TWD in FY2021, a compound −2.6%/yr. Reported net income was 67.3M TWD in FY2025, compounding +0.8%/yr from FY2021.

Growth Quality 69/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
804M TWD
Latest YoY
+2.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.0%
Avg. growth/yr (23Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.0%
Revenue −2.6%/yr
FY21 895M TWD
FY22 845M TWD
FY23 655M TWD
FY24 788M TWD
FY25 804M TWD
Net income +0.8%/yr
FY21 65.2M TWD
FY22 32.8M TWD
FY23 49.3M TWD
FY24 97.3M TWD
FY25 67.3M TWD
Character of growth · EPS growth decomposed (2014-2025) +2.3 % p.a.
Revenue per share +0.3 pp

of which total revenue +0.3 pp · buybacks/dilution +0.0 pp

EBIT margin +0.4 pp
Tax rate +0.0 pp
Residual (interest, one-offs) +1.7 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

1470 screens 31% overvalued. Compare with Shenzhou International Group →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "evertex fabrinology limited Fair Value". https://www.fairvalue-calculator.com/stock/1470

Peer Group

Textile Manufacturing · 307 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside −31% · Below median
Return on equity (TTM) 8% · Above median
Return on assets 5% · Top 25%
Net margin (TTM) 10% · Top 25%
Operating margin (TTM) 12% · Top 25%
Revenue growth -11% · Below median
Dividend yield (TTM) 2.8% · Above median

Valuation Multiples vs Textile Manufacturing median · lower = cheaper

P/E (TTM) 29.4× · Pricier than median
P/B 1.94× · Pricier than 75% of peers
P/S (TTM) 2.52× · Pricier than 75% of peers
P/FCF 0.8× · Pricier than median
EV/EBITDA 13.2× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 7
FUTURE 0 · sector 0
PAST 30 · sector 15
HEALTH 0 · sector 95
DIVIDEND 57 · sector 34

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Textile Manufacturing stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Shenzhou International Group 2313 HK$44.40 HK$75.65 +70%
Tongkun Group 601233 ¥23.56 ¥14.53 -38%
Inner Mongolia ERDOS Resources Co 600295 ¥12.04 ¥14.35 +19%
Far Eastern New Century Corporation 1402 27.55 TWD 28.72 TWD +4%
K.P.R. Mill Limited KPRMILL ₹1,083 ₹467.49 -57%
HMT (Xiamen) New Technical Materials Co 603306 ¥78.00 ¥11.85 -85%
Zhejiang Orient Holdings 600120 ¥5.18 ¥2.21 -57%
Vardhman Textiles Limited VTL ₹602.20 ₹437.53 -27%
Isiklar Enerji ve Yapi Holding IEYHO 174.20 TRY 323.84 TRY +86%
Bros Eastern.,Ltd 601339 ¥8.08 ¥7.87 -3%

Compare evertex fabrinology limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is evertex fabrinology limited (1470) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 16.05 TWD versus a price of 23.40 TWD, about −31% (overvalued).
What is the fair value of 1470?
Our model-based fair value for evertex fabrinology limited is 16.05 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 23.40 TWD.
What is the quality score of 1470?
evertex fabrinology limited has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of evertex fabrinology limited (1470)?
evertex fabrinology limited reported trailing-twelve-month revenue of about 781M TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 1470?
The net profit margin of evertex fabrinology limited is about 9.5%, meaning it keeps roughly 9.5% of revenue as net income. Based on the latest reported figures.
Does evertex fabrinology limited pay a dividend?
evertex fabrinology limited currently shows a dividend yield of about 2.86% relative to its recent price (as of Jul 23, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track evertex fabrinology limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.